Home > Back to Publisher > Report Information

Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006: Market Insights and Trends in a Primary Import Destination

Spectra Intelligence
August 1, 2006
110 Pages - SKU: SPIN1666348

Abstract Table of Contents Search inside this report Related Reports

Countries covered: United Kingdom

The United Kingdom (UK) is the top destination for parallel imported drugs. Approximately 20% of all National Health Service (NHS) dispensed drugs are parallel imports and the market is estimated to be valued at over £1 billion (US$1.8 billion).

Importing drugs into the UK is highly attractive for several reasons:

The relatively high prices of domestically supplied drugs compared with European counterparts
Government incentives encouraging pharmacists to source and dispense parallel-traded drugs through the clawback scheme
The legal and regulatory framework to import and redistribute drugs within the EU is centralized in the UK

This report introduces the reader to the scope of parallel trade in the UK based on therapy area analysis of PILs granted through a 7-year period and assessments of parallel import activities that impact on the domestic market.

Report key findings and highlights:

Outlines the extent and impact of parallel importation in the UK
In-depth analysis of import licence trends across 19 therapy areas
Reviews factors driving growth of parallel trade in Europe and UK
Analysis of over 12,000 parallel import licence approvals from 2000 to June 2006
Provides insight into the actives most commonly targeted for importation
Reveals multinational company portfolios most targeted for parallel importation
Describes the advantages and disadvantages of parallel trade in Europe
Provides an update on parallel importation trends in the UK over a 7-year period
Shows difficulties in assessing true market value of the parallel trade sector
Highlights the leading parallel importers in the UK
Provides competitive intelligence on stakeholders in the parallel trade market
Discusses the future of parallel trade in the UK
Provides background data for customized market research and analysis in the UK parallel import market

Why buy this report

The reader will learn about:

How parallel trade in Europe and the UK has evolved over the past decade
What impact parallel trade has on stakeholders in the UK
How import product areas are changing and why the product lines are expanding
Evaluating the potential for new opportunities in parallel trade, hence stay one-step ahead of the game
Benchmarking potential import-based portfolio losses or gains against competitors
Which strategies are employed by pharmaceutical companies to combat parallel trade

Additional Information

Companies mentioned

3M HEALTH CARE, ABBOTT LABORATORIES, ALCON, ALLERGAN, ALLIANCE, ALPHARMA,ALTANA, AMDIPHARM/WAYMADE, ASTELLAS, ASTRAZENECA, BAYER, BOEHRINGER INGELHEIM,BOLTON, BRISTOL-MYERS SQUIBB, BRITANNIA, CEPHALON, CHEMIDEX, CHIRON, CLINIMED, CROOKES,DR FALK, EISAI, FERRING, FLYNN, GALDERMA, GALEN, GENUS, GLAXOSMITHKLINE, GOLDSHIELD, GRUNENTHAL, IVAX, JOHNSON & JOHNSON, KING, LEO, LILLY, LUNDBECK, MEDA, MENARINI, MERCK, MSD,NAPP, NORGINE, NOVARTIS, NOVO NORDISK, ORGANON, ORION, PFIZER, PIERRE FABRE, PLIVA,PROCTOR & GAMBLE, RECORDATI, ROCHE, SANKYO, SANOFI AVENTIS, SCHERING HC, SCHERING-PLOUGH, SCHWARZ, SERONO, SERVIER, SEVEN SEAS, SHIRE, SOLVAY, STIEFEL, TAKEDA, TRINITY-CHIESI,UCB,VALEANT,VIATRIS,WOCKHARDT, WYETH, ZENEUS.

List of Tables
List of Figures
Executive Summary: Objectives of the Report; Research Methodology
Chapter 1. Introduction to Parallel Trade: Introduction to Parallel Trade; Key Stakeholders; Pack Management
Chapter 2. Parallel Import Analysis by Therapy Area: United Kingdom: Analysis of Authorized Parallel Import Licences, 1995-2006; Parallel Import Approvals by Therapy Area; Analysis of Parallel Import Approvals by Drug Class and Active Ingredient
Chapter 3. The Market for Parallel Importation in the United Kingdom: Pharmacists and Parallel Imports; Growth of Parallel Imports in the United Kingdom; The Euro and Currency Exchange Rates; Parallel Importers: Assessing Market Value; Pharmaceutical Companies Affected by Parallel Imports; Portfolio Analysis; The Future of Parallel Trade in the United Kingdom
List of Tables: Table 1.1 Countries of the European Economic Area (EEA) and Accession Countries; Table 1.2 Main Parallel Import and Export Countries; Table 1.3 Parallel Trade: Main Advantages and Disadvantages; Table 1.4 Anti-Parallel Trade Strategies; Table 1.5 Members of the British Association of European Pharmaceutical Distributors, 2006; Table 1.6 Members of the European Association of Euro-Pharmaceutical Companies, 2006; Table 2.1 Parallel Import Licences (PILs) Authorized in the United Kingdom, 1995-2006; Table 2.2 Authorized Importable Drug Formats in the United Kingdom by Therapy Area, 2000-2006; Table 2.3 Cardiovascular Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.4 Central Nervous System Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.5 Dermatology Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.6 Anti-Infective Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.7 Musculoskeletal Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.8 Obstetric-Gynaecologic Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.9 Oncology Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.10 Ophthalmic Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.11 Pain Based Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 2.12 Respiratory Drug Formats Approved for Parallel Importation in the United Kingdom, 2000-2006; Table 3.1 Parallel Importers in the United Kingdom, 2000-2006; Table 3.2 Top 50 Parallel Traders in the United Kingdom Based on Import Licence Approvals, 2000-2006; Table 3.3 Annual Revenues of Parallel Importers in the United Kingdom (GB£); Table 3.4 Pharmaceutical Companies Affected by Parallel Importation in the United Kingdom, 2000-2006
List of Figures: Figure 1.1 Factors Involved in the Success of Parallel Trade in Pharmaceuticals; Figure 1.2 Main Obstacles and Barriers in Pharmaceutical Parallel Trade; Figure 2.1 Trends of Parallel Import Licence (PIL) Approvals in the United Kingdom, 1995-2005; Figure 2.2 Ranking of Imported Actives in the United Kingdom by Therapy Area, 2000-2006; Figure 2.3 Allergy Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Figure 2.4 Cardiovascular Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.5 Percentage Share of Cardiovascular Based Import Licences by Drug Class, 2000-2006; Figure 2.6 Central Nervous System Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.7 Percentage Share of Central Nervous System Based Import Licences by Drug Class, 2000-2006; Figure 2.8 Dermatology Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.9 Percentage Share of Dermatology Based Import Licences by Drug Class, 2000-2006; Figure 2.10 Endocrine-Metabolic Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Figure 2.11 Endocrine-Metabolic Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.11 Gastrointestinal Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Figure 2.12 Gastrointestinal Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.13 Genito-Urinary Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Figure 2.14 Genito-Urinary Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.15 Immune System Drugs Approved for Parallel Importation in the United Kingdom, 2000-2006; Figure 2.16 Immune System Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.17 Anti-Infectives Approved for Importation by Licence Volume, 2000-2006; Figure 2.18 Percentage Share of Anti-Infective Import Licences by Drug Class, 2000-2006; Figure 2.19 Musculoskeletal Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.20 Percentage Share of Musculoskeletal Import Licences by Drug Class, 2000-2006; Figure 2.21 Obstetric-Gynaecologic Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.22 Percentage Share of Obstetric-Gynaecologic Import Licences by Drug Class, 2000-2006; Figure 2.23 Oncology Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.24 Percentage Share of Oncology Import Licences by Drug Class, 2000-2006; Figure 2.25 Ophthalmic Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.26 Percentage Share of Ophthalmic Import Licences by Drug Class, 2000-2006; Figure 2.27 Pain Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.28 Percentage Share of Pain Based Import Licences by Drug Class, 2000-2006; Figure 2.29 Respiratory Drugs Approved for Importation by Licence Volume, 2000-2006; Figure 2.30 Percentage Share of Respiratory Based Import Licences by Drug Class, 2000-2006; Figure 3.1 Multinational Pharmaceutical Companies Most Targeted by Parallel Importers, 2000-2006

More United Kingdom Regulation & Policy Reports

Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the United Kingdom by JustPharmaReports.com
In an otherwise volatile pharmaceutical world, 2009 has seen two notable and durable anniversaries, the implementation of the tenth re-negotiated Pharmaceutical Price Regulation Scheme in ...

Pricing & Reimbursement of Medicines in the United Kingdom by Urch Publishing
National pharmaceutical pricing and reimbursement is a complex and ever-changing area. In a rapidly evolving market it is essential that executives are briefed on the ...

Pricing & Reimbursement 2002 - Examination of U.S, UK & European Regional Markets for Prescription Pharmaceuticals by Visiongain
The new report Pricing and Reimbursement 2002 is the only comprehensive source of information that will successfully guide you through the maze of different pricing ...

See all reports like this >>

More United Kingdom Reports

A Comprehensive Study Of The UK Video Conferencing Equipment Market In 2010, Rating & Valuing Each Of The 30 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Tableware Market In 2010, Rating & Valuing Each Of The 166 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Surveyors & Valuers Market In 2010, Rating & Valuing Each Of The 943 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Subsea Engineering Market In 2010, Rating & Valuing Each Of The 142 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

A Comprehensive Study Of The UK Structural Engineering Consultancy Market In 2010, Rating & Valuing Each Of The 300 Companies That Operate In Today's Market by Plimsoll Publishing Ltd.
The Plimsoll Analysis provides you with the most up to date and comprehensive analysis of the top 9 companies operating the market. It is ...

See all reports like this >>

Pharmaceutical Parallel Trade in the United Kingdom, 2000-2006: Market Insights and Trends in a Primary Import Destination

Share this report

Other tasks

Research Assistance

Related Markets

Regulation & Policy Reports

Free Alert Me service